Related Experiment Video
Updated: Jun 23, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.2K
Tumor marker elevations in chronic kidney disease: a retrospective study
Liuxia You1, Zhongying Xu2, Qiaoling Liu1
1Department of Clinical Laboratory, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Peerj
|April 7, 2025
Summary
Elevated tumor markers like pro-gastrin-releasing peptide (proGRP) and human epididymis protein 4 (HE4) are observed in chronic kidney disease (CKD) patients. These markers show potential for early detection of renal dysfunction.
Area of Science:
- Nephrology
- Oncology
- Biomarker Discovery
Background:
- Chronic kidney disease (CKD) affects a significant population globally.
- Early detection of renal dysfunction is crucial for effective management and improved patient outcomes.
- Tumor markers are increasingly being investigated for non-oncological applications.
Purpose of the Study:
- To compare tumor marker levels in patients with CKD versus healthy individuals.
- To identify potential tumor markers for monitoring early renal dysfunction.
- To investigate the correlation between tumor markers and CKD staging.
Main Methods:
- Retrospective study of 522 participants (172 CKD patients, 350 controls).
- CKD patients categorized into stages (CKD1-5) based on estimated glomerular filtration rate (eGFR).
- Analysis of plasma creatinine, general clinical data, and various tumor biomarkers including CA125, CA15-3, CA19-9, proGRP, HE4, CEA, and NSE.
Main Results:
- Elevated levels of CEA, CA125, CA15-3, CA19-9, NSE, proGRP, and HE4 were found in CKD patients compared to controls (p < 0.05).
- These markers remained elevated even in CKD patients with normal serum creatinine.
- ProGRP and HE4 demonstrated high predictive values for early renal insufficiency (AUC 0.736 and 0.931, respectively).
- HE4 and proGRP showed positive correlations with CKD stages (r=0.623 and r=0.712, respectively).
Conclusions:
- Patients with CKD exhibit higher levels of several tumor markers.
- Tumor markers, particularly proGRP and HE4, show promise as indicators for the early diagnosis of renal impairment.
- Further research is warranted to validate these findings and explore clinical applications.
Related Concept Videos
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...